Crystal Mackall

The Mark Foundation Announces 2023 Endeavor Awards; $12 Million in Grants for Collaborative Cancer Research Projects

Retrieved on: 
Tuesday, October 17, 2023
Diagnosis, Broad Institute, Tobacco Products Scientific Advisory Committee, Doctor of Philosophy, Memorial Sloan Kettering Cancer Center, Obesity, Inflammation, Crystal Mackall, Endeavor Award, Cancer, Patient, Endeavour, Science, Medicine, News, Research, Vaccine, Management, MD

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- The Mark Foundation for Cancer Research announced the recipients of its 2023 Endeavor Award program, providing a total of $12M across seven institutions to support teams of scientists tackling a range of urgent challenges in the prevention, diagnosis, and treatment of cancer. These $3 million grants are awarded over a three-year term to accelerate progress in high-priority research areas through a collaborative approach.

Key Points: 
  • These $3 million grants are awarded over a three-year term to accelerate progress in high-priority research areas through a collaborative approach.
  • The finalists participated in a rigorous selection process, including live interviews conducted by The Mark Foundation's Scientific Advisory Committee, chaired by Ross Levine, MD, of Memorial Sloan Kettering Cancer Center.
  • "These four teams of scientists are poised to take on some major questions in cancer research," said Dr. Levine.
  • For more detailed information, project titles link to the corresponding project summary on The Mark Foundation website.

CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies

Retrieved on: 
Wednesday, March 1, 2023
Janus, B-ALL, Disease resistance, JD, Transplant, Therapy, Safety, Doctor of Philosophy, Cancer, MD, Survival, Leukapheresis, Crystal Mackall, Breakthrough therapy, CD19, Disease, CAR, Engineering, Nex Entertainment, B-cell lymphoma, FDA, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cellular, ORR, T. Rowe Price, CD22, Third Rock Ventures, LP, Canadian Aviation Regulations, Emerson Collective, Investment, Wellington Management Company, CR, RTW, Food, Financial services, Pharmaceutical industry, Vaccine, Blood

SAN MATEO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced the close of a $200 million oversubscribed and upsized Series A financing. The financing was co-led by Third Rock Ventures, RTW Investments, LP and Perceptive Xontogeny Venture Fund, and includes additional new investors Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management, funds and accounts advised by T. Rowe Price Associates, Inc., Cormorant Asset Management and Piper Heartland. Founding investor Samsara BioCapital and existing seed investors Red Tree Venture Capital and Emerson Collective also participated in the financing. CARGO is advancing what will potentially be a first and best-in-class autologous CD22 chimeric antigen receptor T-cell (CAR T) therapy as well as a pipeline of next generation CAR T-cell therapies for cancer using its proprietary cell engineering platform technologies.

Key Points: 
  • Founding investor Samsara BioCapital and existing seed investors Red Tree Venture Capital and Emerson Collective also participated in the financing.
  • CARGO also intends to advance its proprietary platform technologies and discovery-stage programs to deliver better outcomes for patients with cancer who have high unmet need.
  • CARGO Therapeutics is building upon deep expertise in understanding resistance to CAR T-cell therapies to deliver next generation cell products for patients,” said Gina Chapman, CEO of CARGO Therapeutics.
  • The founders' overarching mission was to overcome CAR resistance to extend the clinical benefit of CARs for patients in need.

SITC Announces Keynote Speaker Dr. Padmanee Sharma and Keynote Panel Honoring the Work of Dr. Zelig Esshar at its 37th Annual Meeting

Retrieved on: 
Thursday, May 19, 2022
Crystal Mackall, MD Anderson Cancer Center, Convention center, Boston Convention and Exhibition Center, Doctor of Philosophy, Society for Immunotherapy of Cancer, Science, Pleasure, Patient, University, Government, SITC, Keynote, Immunotherapy, Industry, Facebook, Conference, YouTube, Society, LinkedIn, Twitter, CAR, Cancer, Medicine, MD

MILWAUKEE, May 19, 2022 /PRNewswire-PRWeb/ -- This year the Society for Immunotherapy of Cancer (SITC) has the pleasure of welcoming Padmanee Sharma, MD, PhD from The University of Texas MD Anderson Cancer Center as the Keynote Speaker at its 37th Annual Meeting and Pre-Conference Programs. Her focus is on the mechanisms of response and resistance to immune checkpoint therapy. SITC is also hosting a special panel to honor the work of Zelig Eshhar, PhD, the 2022 recipient of the Richard V. Smalley Memorial Award. Panel members include luminaries Carl June, MD, Crystal Mackall, MD, Steven Rosenberg, MD, PhD, and Michel Sadelain, MD, PhD.

Key Points: 
  • SITC is also hosting a special panel to honor the work of Zelig Eshhar, PhD, the 2022 recipient of the Richard V. Smalley Memorial Award.
  • Panel members include luminaries Carl June, MD, Crystal Mackall, MD, Steven Rosenberg, MD, PhD, and Michel Sadelain, MD, PhD.
  • SITC is also hosting a special panel to honor the work of Zelig Eshhar, PhD, the 2022 recipient of the Richard V. Smalley Memorial Award.
  • Panel members include luminaries Carl June, MD, Crystal Mackall, MD, Steven Rosenberg, MD, PhD, and Michel Sadelain, MD, PhD.

Ensoma Strengthens Scientific Advisory Board with Leaders in Oncology and Primary Immune Deficiencies

Retrieved on: 
Thursday, October 28, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Genetics, Takeda, Disease, NIH, CAR, Stanford University, Cell, NIAID, Crystal Mackall, Degenerative disease, National, Pediatrics, Inflammation, Lists of diseases, National Institute, Haematopoietic system, Gene, Immune system, Division, Health, HIV, National Institute of Allergy and Infectious Diseases, Engineering, Biology, Research, Blood, Virology, UCSF School of Medicine, Immunodeficiency, Ernest, HSC, University of California, Genetics, Stanford University School of Medicine, Hemoglobinopathy, Infection, Hospital, UCSF, Microbiology, Society, Transplant, University, Cancer, Patient, Stem cell, Fred Hutchinson Cancer Research Center, SAB, Physician-scientist, Pharmaceutical industry, Vaccine, Medical device

We are excited to have assembled such an accomplished and diverse group of academic, scientific and clinical experts to serve on our scientific advisory board, said Robert Peters, Ph.D., chief scientific officer of Ensoma.

Key Points: 
  • We are excited to have assembled such an accomplished and diverse group of academic, scientific and clinical experts to serve on our scientific advisory board, said Robert Peters, Ph.D., chief scientific officer of Ensoma.
  • Her work includes utilizing transposons and designer nucleases within adenoviral vectors for achieving permanent treatment effects.
  • Our Engenious gene therapy platform is the first to precisely engineer any or all hematopoietic and immune cells with a one-time, off-the-shelf in vivo treatment.
  • Ensoma is supported by top-tier investors, a strategic collaboration with Takeda and a passionate team committed to a bold, global vision for gene therapy.

Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call

Retrieved on: 
Thursday, July 29, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Chimeric antigen receptor T cell, Gene therapy, Immune system, Lymphoma, Branches of biology, Oncology, Crystal Mackall

Following the press release, Celyad management will host a conference call on Thursday, August 5 at 2 p.m. CEST / 8 a.m. EDT to discuss first half 2021 results and provide an update on the Companys recent progress and upcoming milestones.

Key Points: 
  • Following the press release, Celyad management will host a conference call on Thursday, August 5 at 2 p.m. CEST / 8 a.m. EDT to discuss first half 2021 results and provide an update on the Companys recent progress and upcoming milestones.
  • To access the live webcast and archived recording, visit the " Events " section of the Celyad website.
  • Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.

Celyad Oncology to Host Virtual Research & Development Webinar on July 20th

Retrieved on: 
Tuesday, July 13, 2021
Clinical medicine, Medicine, Branches of biology, Cancer immunotherapy, Chimeric antigen receptor T cell, Gene therapy, Immune system, Lymphoma, Cellectis, Crystal Mackall

MONT-SAINT-GUIBERT, Belgium, July 13, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it will host a Research & Development webinar on Tuesday, July 20th at 11:30 a.m. EDT.

Key Points: 
  • MONT-SAINT-GUIBERT, Belgium, July 13, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it will host a Research & Development webinar on Tuesday, July 20th at 11:30 a.m. EDT.
  • The live webcast of the presentation can be accessed by visiting the Events section of the Celyad Oncology website.
  • After the conclusion of the event, a replay of the webcast will also be available on the Celyad Oncology website.
  • Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.

Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021

Retrieved on: 
Wednesday, July 7, 2021
Clinical medicine, Leukemia, Medicine, Chimeric antigen receptor T cell, Gene therapy, Immune system, Lymphoma, Branches of biology, Oncology, Crystal Mackall

The management team will participate in one-on-one investor meetings throughout the conference as well.

Key Points: 
  • The management team will participate in one-on-one investor meetings throughout the conference as well.
  • A live audio webcast of the discussion can be accessed through the Events section of the Companys website.
  • Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.

Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call

Retrieved on: 
Thursday, March 18, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Chimeric antigen receptor T cell, Gene therapy, Immune system, Lymphoma, Branches of biology, Crystal Mackall, Kite Pharma

Following the press release, Celyad management will host a conference call on Thursday, March 25 at 1 p.m. CET / 8 a.m.

Key Points: 
  • Following the press release, Celyad management will host a conference call on Thursday, March 25 at 1 p.m. CET / 8 a.m.
  • ET to discuss full year 2020 results and provide an update on the Companys recent progress and upcoming milestones.
  • Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncologys pipelines and financial condition, results of operation and business outlook.

Information on the Total Number of Voting Rights and Shares (Articles 15 of the Law of 2 May 2007)

Retrieved on: 
Wednesday, January 20, 2021
Clinical medicine, Medicine, Branches of biology, Cancer immunotherapy, Chimeric antigen receptor T cell, Gene therapy, Immune system, Lymphoma, Coronavirus disease, Crystal Mackall, Kite Pharma

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.

Key Points: 
  • Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.
  • The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs.
  • Such risk and uncertainty include the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto.

Celyad Oncology to Participate in a Fireside Chat at the JMP Securities Hematology Summit

Retrieved on: 
Tuesday, December 1, 2020
Clinical medicine, Medicine, Cancer, Cancer immunotherapy, Chimeric antigen receptor T cell, Gene therapy, Immune system, Lymphoma, Oncology, Crystal Mackall

A live and archived webcast of the presentation will be available in the Events section of the Celyad Oncology website.

Key Points: 
  • A live and archived webcast of the presentation will be available in the Events section of the Celyad Oncology website.
  • Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.
  • This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995.